Stockholm3

About A3P Biomedical

A3P Biomedical is a private, commercial-stage diagnostics company with a validated product, Stockholm3, for prostate cancer risk stratification. The test has demonstrated superior performance compared to the standard PSA test, finding more aggressive cancers while reducing over-diagnosis, as shown in studies involving over 90,000 men. With recent leadership appointments and inclusion in major clinical guidelines, the company is positioned for growth in the global prostate cancer screening market. Its business model is centered on the commercialization of its diagnostic test.

Therapeutic Areas